text:
Raj Palace
Chennai (Madras), India (MAA)
Check Rates for
Hotel Specials
Hotel Specials
Hotel + Flight from
Check Rates for
Package Specials
Package Specials
Check Rates for
Package Specials
Package Specials
Room & Rates
Raj Palace
12/1, Thanikachalam Road, T.Nagar, Chennai, India 600017
Based on 80 reviews 0
Be the first person to review this property!
Raj Palace COMFORTABLE PLACE
vaishnodev_17 from Guwahati, India
Submitted on 12-04-2016
After a tiring journey it is nice to see a comfortable and clean bed room though a little compact. Bathrooms are clean , have good toiletries but not spacious. Room service is very good . Food is also delicious.Breakfast is complimentary though the choice is less .Location of the hotel is a great advantage. Though it is centrally located rooms are free from any noise.Good place to stay for a short stay.
|Sleep Quality
Raj Palace Excellent staff, Rude manager
TenicePillay from
Submitted on 11-22-2016
I would have definitely given this hotel a 5 star rating. Lived in India for 32 days and spent my last 3 nights in Raj Palace. The staff are amazing. Restaurant waiters are friendly and ever so willing to explain the menu. The gentlemen at reception were extremely helpful and always had a smile on their faces, irrespective of the time. Everything was going just perfect then I witnessed the rudeness and arrogance of the hotel manager to his staff in our presence. Even though he spoke to them in t... I would have definitely given this hotel a 5 star rating. Lived in India for 32 days and spent my last 3 nights in Raj Palace. The staff are amazing. Restaurant waiters are friendly and ever so willing to explain the menu. The gentlemen at reception were extremely helpful and always had a smile on their faces, irrespective of the time. Everything was going just perfect then I witnessed the rudeness and arrogance of the hotel manager to his staff in our presence. Even though he spoke to them in tamil, he used a few English words and his facial expressions and tone of voice was shocking. He was so rude to the two waiters and even told them to shut up. At the end of the conversation he told them go get out. I did confront him then and there about his lack of work ethics. And all he said was sorry. This incident took place on the 18th of November around 11pm. The location is good. A 5 minute walk to the shopping area. However Raganathan Street has better shopping. The breakfast is good and the rooftop restaurant serves delicious food. Read more
Raj Palace centrally located and comfortable
mahalakshmii2016 from
Submitted on 11-14-2016
Rooms are neat and comfortable though compact. location is a great advantage. room service is great. Morning complimentary breakfast is good. Mini conference hall is hindrance to the occupants as the lobby to the rooms in first floor is mostly occupied by the seminar hall participants. other than that, hotel is great.
Raj Palace Above average hotel
BVibhavari from Mumbai (Bombay), India
Submitted on 10-26-2016
the rooms are little compact and could be good only for short stay, budget hotel good connectivity of internet, breakfast has little choice and not really wide range, however the swimming pool seems good,,
|Sleep Quality
Raj Palace Average place
immortalmechano from
Submitted on 10-06-2016
It's an average place that's showing its age now. Not so well maintained. Great location so it's a great choice for people on a budget and want to stay in T nagar. Not neat enough for families now so much.
Raj Palace Excellent location in T.Nagar close to everything from shopping for jewellery to sarees and to many parts of the city.
Mohan K from
Submitted on 09-17-2016
Coming from U.S., we enjoyed staying here for the last 10+ years. Reasonably priced for comfortable cozy rooms. Excellent round the clock service with personal attention. On site restaurant with good food and round the clock room service including laundry. Check it out. You will be happy you did.
|Sleep Quality
Raj Palace One night stay--its good
hari s from Bengaluru, India
Submitted on 08-17-2016
first of all its in heart of the city anna nagar everything is accessible and rooms are clean and neat...even break fast was good all the hotel management ppl are professional and even coperative could stay easily in chennai with families!
Raj Palace Centrally located
Prajyot7 from Pune, India
Submitted on 08-17-2016
Hotel location is very good. Rooms are clean with attached bathroom. Having ground floor restaurant. Breakfast is very good. Road side in front of hotel parking is available. Free Wi-Fi, some complimentary things are available like drinking water bottles.
Raj Palace Good business hotel for a short business trip
Ashp05 from Mumbai (Bombay), India
Submitted on 07-11-2016
The hotel is located very near to the central market of chennai and hence makes a good place to stay if one needs access to the city. The rooms are comfortable, however the hotel can do better in terms of its facilities and amenities. Food quality is ok and food is hygienic. overall friendly people who are willing to help.
|Sleep Quality
Raj Palace Nice hotel comfortable stay
Champakonline from Mumbai (Bombay), India
Submitted on 06-05-2016
Stayed during my business trip. Location is good. Hospitality is really good and all staff are very cooperative. Rooms are big enough comparative to other same rate hotel in that area. Wifi is free with good speed and coverage. The main attraction is the roof top restaurant. There is also a bar at the basement which is good to hang out. Foods rate are reasonable. Buffet breakfast is limited with mostly south Indian dishes. Overall good experience. Will consider for my next tour for sure.
|Sleep Quality
Similar Hotels


text:
Krysta (コキュートス, Kokyūtosu?, lit. Cocytus) is a recurring ability in the series.
Crisis Core -Final Fantasy VII-Edit
Krysta is an enemy ability used by Minerva, which inflicts massive non-elemental magic damage to Zack. It requires extremely precise timing to dodge through to avoid taking any damage at all.
Final Fantasy XEdit
Krysta is an ability used via Rikku's Mix command, which inflicts three hits of major Ice-elemental damage to all enemies, as well as Poison, Darkness, Silence, Sleep, and Full Break for three rounds.
Final Fantasy X-2Edit
Krysta is an ability used via the Mix command, which inflicts three hits of 300 Ice-elemental damage and Sleep to random enemies.
Final Fantasy Airborne BrigadeEdit
Cocytus, meaning "the river of wailing," is a river in the underworld in Greek mythology. In Dante's Inferno, Cocytus is the ninth and lowest circle of Hell where traitors are frozen in a lake of ice, Satan is imprisoned waist deep in ice at the very center of Hell.

subset: commoncrawl


text:
Hello Ladies, a little bit about me...I'm nearly 40 with 3 children (19,16 and 11) and a supportive fiancé. 6 years ago I was a UK size 20/22 but now I'm a UK size 16 but now I have very saggy deflated breasts. I am currently a small 40C but would love to be an E/F. I have thought about getting a BL and BA for the last few years and over the past year I have been reading about all of your journeys, ups and downs and picking up tips and advice and now thanks to all of you lovelies and lots of research, I feel ready to go ahead. So I had my consultation with Dr Frank Plovier last month at his Harley Street clinic and booked my surgery with him for the 14th July. I found him to be straight and to the point but I felt very comfortable with him, He answered most of my questions before I had even asked and talked me through my options. We agreed on an anchor lift with implants. He asked me if I had any pictures with me of the look that I wanted so I showed him a few and he said it was achievable but I would need larger implants to get the look I was after. He did mention 1050cc silicone implants. I have had a mixture of excitement and nerves ever since and keep thinking of lots of silly little questions and things that I need to remember to ask or buy before I head off to Belgium. If any of you have been to Beclinic or have any advice, it would be gratefully received. I can't wait to be proud of my breasts again. Bring on the boobies.
Curvy, Nearly 40,having an Anchor Lift and 1050 Implants with Dr Plovier in Belgium. Belgium, BE
Hello Ladies, a little bit about me...I'm nearly...
Was this review helpful? {{ voteCountOthers + ' other' + (voteCountOthers == 1 ? '' : 's') }} found this helpful


text:
Working out for the scouts were: Mark Anderson, Rudy Griffin Roman Harper, Victor Horn, Ray Hudson, Juke King, Canary Knight, Drew Lane, Anthony Madison, Charlie Peprah, Freddie Roach and Ryan Saxby.
Anderson, who was working drills with the linebackers was happy with his NFL combine time and did not run the 40-yard dash Wednesday, but Roach and Ryans both tried - and apparently succeeded - at improving their times.
"The only thing I did here (besides position drills) was the 40. I let them go off the combine for everything else," Ryans said. "I ran better. I don't know specifically, some people had me at 4.59 and some people had me at 4.61."
Roach also suspected he improved his run, breaking below the 4.7 mark by at least one hand timing.
Ray Hudson said some of the scouts had him at 4.4 in the 40. Each player was given two runs.
Representatives from the Lions, Raiders, Giants, Jets, Seahawks, Redskins, Colts, Titans, Ravens, Packers, Browns, Bengals, Buccaneers, Texans, Steelers, Patriots, Bears, Vikings and Chargers were all spotted at Wednesday's workout.
Chuck Bresnahan, the defensive coordinator for the Cincinnati Bengals attended.
Ryans, who benched 225 pounds 23 times at the combine, said he's looking forward to being in Tuscaloosa for the April 1st A-Day game to get his hand and cleat print sealed in cement as a part of the captains' ceremonies.
"I've got to put my hand in," he said. "I'm looking forward to that. It's a big accomplishment. When I first set foot on the campus I wanted to be a part of it and my last year to have a chance to do it is great."
As for further draft preparation, Ryans said he's now focusing on getting better at the drills since his times are in. He said he weighed 240 pounds Wednesday, the heaviest he has been.
Ryans wasn't about to speculate on where he might be drafted or by whom.
"I could have my opinion about who's going where but it doesn't matter because you never know what the teams are going to do," he said. "They (outside experts) don't know who's on their draft boards. It's just going off of opinions. Everybody has opinions about the draft just like they have an opinion about the NCAA tournament. You never know what they're going to do."
Croyle was happy about how throwing in front of the scouts to some of his old teammates went.
"I felt really, really good about today," he said. "I threw the ball the best I've thrown it. I think we missed one ball on the whole day so I feel pretty good going into the draft. It's pretty much down time right now."
Croyle has been working with Zeke Bratkowski, a former NFL quarterback and personal coach.
Brodie: "He's helped out a lot, especially coming down here organizing all this making sure we had everybody here," Croyle said. "We went through that workout a couple of times and it paid off for us today. I think we missed one day."
Croyle also declined to guess on where he might go in the draft.
"As soon as you think you're going somewhere they end up getting a quarterback the next day."
The Chargers talked to Croye after practice, and it should be noted that this is the third time they have had discussions of some kind with the 'Bama QB.
Croyle, of course, will also be at the A-Day game to put his hand and cleat print in the cement. He is looking forward to the event and said the interaction he's had with Alabama fans since the Cotton Bowl has been incredible.
"It's been awesome. You couldn't ask for better," he said. "Alabama fans are the best. Us going out the way we went out in the Cotton Bowl made our legacy that much sweeter and it's been a blast. I don't have one regret about coming to this school and never will."
Related: Alabama Draft Eligible Players || Alabama Football Articles || Full Draft Rankings


text:
About a month ago Albee Layer landed his — and the world's — first backside 540.
It was a trick he'd been trying for a year and a half, a huge weight off his shoulders and a giant leap forward in the progression of aerial surfing. Buuuuuuuut nobody filmed it. Oops. Fast-forward to Friday evening and, after a month of beating his body and mind in pursuit of landing the trick again, Albee sticks another one. This time was bigger and cleaner than the first and, wouldn't you know it, the cameras were rolling. We spoke with Albee on Saturday about the historic trick, why John John didn't land it first and how Kelly responded to the clip.
Interview by Taylor Paul
SURFING: Tell us about yesterday.
ALBEE LAYER: We saw that it was going to be good for Lanes, the wave right next to Ho'okipa, and by "good" I mean washing through and really windy and every now and then there's a good section. That's where I'd gotten the closest so far, and where I landed the one that no one filmed. We got out there in the afternoon and it was me, Matt [Meola] and [Kai] Barger, and my friend Marlon. They had a couple good airs but there were a lot of wash through sets. It's pretty easy to get frustrated and just go in on those days 'cause you can get washed in, paddle all the way back out, get washed in again, paddle back out and not even catch a wave. And that's kinda how it was going for me most of the session. Then Matt cut his foot trying an air and he had to go get stiches. So him, Barger and Marlon went in. Then Kain Daly paddled out, which is funny, because Kain's been there for this whole uphill battle of trying this trick, so once he paddled out I almost felt the vibe improve a little bit. Before that, I hadn't caught a single decent wave and I was just mad, getting washed around. Closeout after closeout. Then finally, this nice little wave came, with a nice section, and it just sorta happened.
What did it feel like to ride out of it? I saw you put your hands on your face…
So I landed backwards, and was kinda tip-toeing and did little air drop and I was like, "Oh my god please don't fall right now." I thought I was going to fall like three times, going, "Oh fuck..oh fuck..oh fuck…" Then I was still standing and it was like, "Shit, there's two people filming, it's probably on footage…I'm done." I was just so relieved. That was the biggest thing, there's just this huge monkey off my back. When I did the alley-oop five I was like pounding my chest and screaming. But with this one, I went into a deep relaxing state like, "yes…done!"
Why were the two different?
I probably tried the alley-oop fewer times. And there was so much hype that Julian was going to do it, so when I did it it was sorta like, "Wow, I beat Julian." People barely knew who I was at that point, so it was kind of an underdog win. Whereas this one, well, John was kinda trying it, but he was so focused on contests this year. I don't know, it didn't really seem like anyone else was trying them, so it just became this personal thing.
You talk about the monkey off your back, but it doesn't seem like anyone else was putting pressure on you except yourself.
Well, it was just like amongst our little group [the Maui guys], they're just like, "Albee, come on, you have to do this. You've gotten so close so many times it just has to happen."
What did it feel like when you landed your first one and nobody filmed it?
[laughs] It was pretty funny. I mean, it was pretty shitty [air]. I rode out for like two seconds and the wave doubled up and went underneath me. But it was like, "Whoa, I think I just did it." And my friend Morris was right there and he was like, "That was it!" And I looked in and saw Dan [Narkunas] sitting there with his head down, waiting for his card to clear, because I had just paddled out. I was like, "Damn it!"
In retrospect, do you think it wasn't meant to be seen, because it was kind of a half-landing?
It was definitely landed, but the one I did yesterday was better. Cleaner landing and just better all around. At the time, I was just stoked I did it, but then I tried for the next four days to get one on footage and was just wrecking myself. Spinning that fast and slapping the water and getting whiplash, it's harder on your body than trying a normal air. So after already doing it, I was pretty bummed.
It seemed like there was a little bit of a competition going between you and John John on this trick. Was that something you guys were talking about?
We talked about it all the way back during our first trip to West Oz, for Done. He showed me a clip of him over-rotating a backside spin, and I showed him one of me doing the same thing. So it started a bit of a battle. I mean, I think if he put half the energy I did into it he probably would have made it, but this year he just shifted his whole focus onto contest surfing. Which personally, I just hate [laughs], thinking about the progression he could do for surfing.
Do you mean that if he put the same energy into doing new tricks as he does into contests he'd be progressing the sport more?
Yeah…like, ten-fold. I would love to hear someone try and argue me on that. You can see it, even when he was doing his movie. When he was focused on getting the best clips, he'd get the best clips. And because of that everyone would try and surf better to keep up. He was showing everyone what was possible. He won the world title, and that's amazing, but he pretty much disregarded his air surfing, or at least trying new ones.
Is that something you think about doing, elevating the entire sport? Or are these trick progressions just for you?
A little bit of both. It becomes a personal battle, you want to prove to yourself you can do it. But I absolutely want to progress surfing in whatever way I can. I don't know why, I was trying to think about that the other day — what is the point of progressing a sport? I don't know. But surfing's given me all my dreams, so I just want to help make it cooler, I guess.
How long have you been trying the backside 540?
I tried the random one here and there for the last three or four years, but this past year and a half I've put a lot of time into it, trying it pretty much every time we surf good backside air waves. At the beginning of the year I got really close, then the next thing you know I didn't surf a wave that wasn't Jaws for two or three months. I tried more at the end of the season, but my body and brain were just fried.
After you landed this one, did you send John John the video? What did he say?
Yeah, I whored it out pretty hard and sent it to a bunch of people. [laughs] But I wrote John to congratulate him on winning Haleiwa, then I was like, "Guess what?" and sent him the clip. He just wrote, "Fuck you." [laughs] Then he wrote "Wow, you finally did it." And that was it.
Did you send it to Kelly?
Yeah, he said, "8.3." [laughs] And I said, "7.83." And then he said something like, "You coulda done two more floaters, that wave kept on peeling." And then I told him, "My mom said that, literally, without being sarcastic." And he said, "You thought I was being sarcastic?" [laughs]
Ha! World champ of minimizing other people's accomplishments.
It was a pretty funny conversation. He's a clever human, that one.
Why did you decide to release it on @huckleberrysurfco?
It's a fin company that I'm partnered on with my buddy Ross, from San Diego. And then Dege [O'Connel] and Dan [Narkunas] are part owners, and Monyca [Eleogram] rides for us, but will probably own a portion. Anyway, we're getting close to having our first big order of fins in and really making a push for the whole company, so I just wanted to get some more eyes on that. Figure if we get some more followers it'll make things a little easier down the line.
Well, congrats Albee. We're proud of you.
Thanks, man. On to the next…
ALBEE LAYER BACKSIDE DOUBLE SPIN from TAKE SHELTER PRODUCTIONS on Vimeo.


text:
It only takes a minute to get started. Fill out our simple sign up form and login to the site.
This step is voluntary but will dramatically raise your chances of people actually reading your profile and contacting you. Introduce yourself, your hobbies and upload any nice photographs of yourself.
Utilise our website's state-of-the-art search to encounter members who meet your criteria. Or just browse through listings and encounter people that interest you.
Located someone who is attractive to you? Send them a message or just a wink and see if anything develops. With a little luck you'll be on your way to locating that special someone for you.
You won't regret it


text:
Jaipur, Nov 2 (UNI) The pitch of the naxalite movement by MCC and other extremist Maoists groups has started weaning out in naxalite infested areas of Andhra Pradesh, Jharkhand and Bihar, CPI Marxist Leninist Secretary K N Ramchandran said.
Talking to UNI here, Mr Ramchandran said, ''Maoists groups, spearheading naxalite activities from forests, have now been weakened and their activists started eschewing violence.'' He said a number of Maoists had foresaken violent activities to join the CPI(ML) in Jharkhand and Chhattisgarh.
He noted that naxalites were very strong in Andhra Pradesh but their backbone had been broken in that state.
Internal clashes and infighting within these groups had also been reported from Jharkhand and Bihar, Mr Ramchandran said.
Even Nepal Prime Minister Prachanda's Maoists party, after assuming power, had dropped Maoist suffix from its name, he observed.
Mr Ramchandran said these groups did not represent the true Communist ideology but were merely anarchists.
''True Communists do not take contract for themselves to bring a revolution but only work to spread the message among people for bringing a meaningful revolution through the masses. This does not require any anarchist way or undue blood shed,'' he added.
Accordingly, the CPI(ML) was working to build a force capable of mobilising the masses for revolution, Mr Ramchandran said.


text:
CAMBRIDGE – Discussions in Beijing between US President Barack Obama and Chinese President Xi Jinping – the leaders of the world's two largest carbon-emitting countries – produced an unexpected, groundbreaking bilateral agreement on greenhouse-gas emissions. Under the new deal, the US is to reduce its emissions by 26-28% from 2005 levels within 20 years, and China's emissions are to peak by 2030. In the absence of a binding global agreement, such unilateral or bilateral commitments by countries to rein in their contribution to global warming represent the most realistic hope for addressing climate change.
The 1997 Kyoto Protocol marked a major step forward in efforts to head off the most disastrous consequences of climate change, establishing a precedent for legally binding limits on emissions. But it lacked commitments by large developing countries, such as China and India, and, largely for that reason, the United States never ratified the treaty.
A loose system of individual commitments, in which each country unilaterally sets emissions targets, can help build trust and momentum for a more inclusive successor to the Kyoto Protocol, which many hope will be forged at the United Nations Climate Change Conference in Paris in 2015. But if such a system is to work, general agreement would need to exist about what constitutes a fair target for each country. Then advocacy groups and researchers could compile scorecards that would show which countries are meeting the standard – and shame those that are not.
At first blush, there would seem to be no agreement on what fair cuts would look like. India point outs that an average American emits ten times as much as an average Indian, and argues that emissions allowances should therefore be allocated according to population. The US insists that it would be unfair to burden its companies if energy-intensive industries could simply relocate to developing countries that had not yet constrained their emissions. Both sides have a point.


text:
66060 Meyers Landing Road, Sturgis 49091
See more homes for sale in Sturgis, MI
This property has been Sold!
06/10/2016 at $90,000
Great opportunity on All Sports Omena Lake. The very unique lake cottage enjoys water front on 3 sides. Located on the outlet with 72' of lake front with the outlet wrapping around the property. The cottage features 1122 SF of living space, 2 large bedrooms & a full bath. There is an arched bridge over the outlet to the second parcel ID # that features a park like setting wrapped in woods. Forced Air furnace was new in 2011. Sold as a turn key including all furnishings.
Property Information
- Status
- Sold
- Address
- 66060 Meyers Landing Road
- City
- Sturgis
- Zip
- 49091
- County
- St. Joseph
- Township
- Sherman Twp
- Total Finished SqFt
- 1,122
- Above Grade SqFt
- 1,122
- Waterview
- Waterfront
- Waterfront Desc
- All Sports, Private Frontage, View
- Waterfrontage
- 72.0
- Body of Water
- Omena Lake
- Water
- Well
- Sewer
- Septic System
- Year Built
- 1960
- Taxes
- $1,480
Rooms and Land
- MasterBedroom
- 10X18 1st Floor
- Bedroom2
- 9X17 1st Floor
- Bath
- 7X8 1st Floor
- Dining
- 7X8 1st Floor
- Kitchen
- 7X11 1st Floor
- Living
- 12X19 1st Floor
- Basement
- Crawl Space
- Cooling
- Wall Unit
- Heating
- Forced Air, Natural Gas
- Acreage
- 1.5
- Lot Dimensions
- 72 x 114
- Appliances
- Built in Oven, Cook Top, Range, Refrigerator
- Features
- All Window Treatments, Ceiling Fans
- Exterior Materials
- Brick, Vinyl
Listing Video for 66060 Meyers Landing Road, Sturgis MI 49091
Mortgage Calculator
Listing Broker
Listing Courtesy of Re/Max Elite Group
Office Address 26078 Us 12 Hwy Suite A
Listing Agent David L Hochstetler
Listings last updated: . Some properties that appear for sale on this web site may subsequently have been sold and may no longer be available.
Our Michigan real estate agents can answer all of your questions about 66060 Meyers Landing Road, Sturgis MI 49091. Real Estate One, Max Broock Realtors, and J&J Realtors are part of the Real Estate One Family of Companies and dominate the Sturgis, Michigan real estate market. To sell or buy a home in Sturgis, Michigan, contact our real estate agents as we know the Sturgis, Michigan real estate market better than anyone with over 100 years of experience in Sturgis, Michigan real estate for sale.
The data relating to real estate for sale on this web site appears in part from the IDX programs of our Multiple Listing Services. Real Estate listings held by brokerage firms other than Real Estate One includes the name and address of the listing broker where available.
IDX information is provided exclusively for consumers personal, non-commercial use and may not be used for any purpose other than to identify prospective properties consumers may be interested in purchasing.
All information deemed materially reliable but not guaranteed. Interested parties are encouraged to verify all information. Copyright© 2017 MichRIC LLC, All rights reserved.


text:
Sorry you're having a bad experience. Tell us how we can improve...
Not ?
We're excited to introduce you to our brand new site! All the great deals from DealChicken, plus more than 50,000 free coupons from 20,000 more local merchants!
We're excited to introduce you to your new local savings and gift certificate center!We've added offers and listings for over 20,000 local merchants and grown by 109 cities.
What are we asking? Linking accounts means we will allow your Facebook account to access your existing Local Flavor account.
For security purposes, we require you to simply log in with your email and password to confirm this is the account we should link to Facebook.
Warning: If you click NO, but you already have an existing account (with a different email address, for example), you will end up with two different accounts.
Or you can create a brand new Local Flavor account using the info from your Facebook.
Oops, We need your Phone
Mia Regazza celebrates family (after all, their name means "my girls") with huge portions of Mediterranean favorites like delicate Veal Piccata, spicy Seafood Fra Diavolo, slow-grilled Rack Of Lamb, and Pan-Seared Scallops Risotto.
Traditional, gluten-free or whole-wheat pastas are available topped with marinara and meatballs, Alfredo, scampi or bolognese sauces. Taste buds are also tempted by their Grilled Vegetable Panini, Italian Sausage Panini, and Trattoria Burger with roasted red peppers, red onions and fresh mozzarella cheese on grilled sourdough bread with basil pesto mayonnaise.
An extensive wine list and signature martinis are featured (though not included with this offer), and catering is available for any occasion.
When new offers are available from this business.


text:
DiarmaidBHK (854) Lewisburg, Pennsylvania | July 6, 2013
Beers on the far left side next to the wine. Pretty good selection compared to most grocery stores, its only middle of the road by Wegmans standards. solid selection of regional and National craft but a bit lacking in local And Belgian stuff. Its a solid place for a craft sixer but its no destination place.
magsinva (154) Virginia | July 6, 2013
Newer style wegmans with a mixed beer & wine area off at one end. For your typical grocery store, the selection is pretty good, for a wegmans, its about average.
skeate (1) Virginia | August 1, 2011
Apparently, they recently reorganized their beers (roughly) by place of origin--if it used to be this way, Ive forgotten. Best selection that I know of in the area.
ditch (1) Dale City, Virginia | November 1, 2009
This is pretty much the only place in the Woodbridge/Quantico area to get a good selection of craft brews. Its mainly focused on wine and the employees are more wine heads than they are beer heads. The manager in charge of the beer section is very helpful when hes there. But thats not too often, in my experience. They rotate the stock and keep up with the seasonals pretty well. Its not the best selection Ive seen. But if you live in the area you will definitely appreciate their desire to get you what youre looking for.


text:
25th Anniversary, and was our 1st Cruise
Sail Date: June 10, 2016
Reviewed: 1 year ago
Traveled As: Couple
Room Type: Oceanview
Favorite part of the Cruise was getting away from the kids, the chores, cooking & cleaning..., and of course the Casino!!
Too bad the wifi was so horrendous..., as a real estate agent, I had to use the inport time to catch up/follow up with clients..., eventhough we paid for the premier wifi package, I was unable to send or receive email..., on a lighter note, my wife was able to use facebook.
We were also unable to get the Carnival Hub to work..., so when my wife and I were apart, we were really apart..., and had to leave notes in the room for one another...
But it was a great room with a view!!
We can't wait to take another cruise though, and next time we'll be smarter about it!!
All the best, Glen
Category Ratings
Click table then swipe to view all columns.
Click table then swipe to view all columns.
|Cabin / Stateroom
|Squeaky Clean, spacious & very well laid out!!
|Embarkation and Disembarkation
|Ship Quality
|Onboard Activities
|Everywhere we went topside, the music was blaring so loud, we needed hearing protection. Would have really appreciated some piece and quite!!
|Service and Staff
|The service and the staff were exceptional!!
|Food and Dining
Port Ratings
Click table then swipe to view all columns.
Click table then swipe to view all columns.
The wifi sucks, so if it's a "working" getaway..., make other plans!!
5 Comments
Leave a Comment
Remember: Be polite and respectful. Our diverse community is home to members with different opinions and a broad range of cruise experiences.


text:
Stella Does Tricks (18) Coky Giedroyc
The Delta (nc) Ira Sachs
Traveller (18) Jack Green
In the Company of Men is a satire painted in such broad strokes that you may feel obliged to throw tomatoes at the screen. The writer-director Neil Labute doesn't seem to be searching for a much more sophisticated response than that. Certainly he wants the film to be discussed at all the right dinner parties, but he hasn't invested it with the kind of complexity that repays careful analysis.
Its central characters are a pair of obnoxious misogynists. Chad (Aaron Eckhart) is the suave, dominant predator - he's like a walking oil slick, and he sullies whatever he touches. Although Howard (Matt Malloy) is technically Chad's boss, he acts like his stooge, hanging on his every malicious word. Howard must be the one who always got picked on in the playground; he has the appearance of the Milky Bar kid turned plump.
They have both just been dumped by their girlfriends, and decide to wreak their revenge by finding a woman and destroying her. The target of their cruelty is Christine (Stacy Edwards), a young, deaf secretary who works in their office. Chad and Howard take her out on separate dates, engineering parallel romances, and of course, you are appalled by their behaviour - how could you not be?
Labute increases your discomfort by denying Christine's perspective until the final moment, choosing instead to strand you in the men's rooms and bars and office corridors that are Chad and Howard's domain.
This claustrophobia, evoked through intense repetition of shots and locations, is impressively consistent. But Labute sabotages his own objectives by making the film's characters so extreme that you are dissociated from their behaviour. Chad and Howard are a pair of savage, desensitised Iagos, and Christine is no more enigmatic a creation - the camera idolises her to the point where she becomes a bleached-out icon of perfection, pure and innocent and good. Born to be destroyed by beastly middle-management.
The saving grace of In the Company of Men is its formal, sombre style. The film is punctuated by title cards which divide the action into weeks, each card accompanied by an aggressive blast of snarling jazz, but music is conspicuous by its absence from the rest of the picture.
I also liked the chilling anonymity of the business world. The organisation that the characters work for remains nameless, and when Chad leafs through a brochure containing photographs of his company colleagues, he identifies them not by name but by the degree to which he loathes them.
Am I alone in thinking that there has always been something slightly sinister and unctuous about James Bolam? He approaches his role as an avuncular pimp in the gloomy new British film Stella Does Tricks as a cross between Michael Caine in Mona Lisa, Alan Alda in Crimes and Misdemeanours and Robert Mitchum in The Night of the Hunter. He oozes ugliness; after his scenes, you feel like scrubbing yourself clean.
The film follows the efforts of his favourite girl, the teenage Glaswegian Stella (Kelly Macdonald), to escape his clutches. It looks as if she has made it when she hitches up with a fidgety young Jack-the-Lad, played with feline grace by Hans Matheson, only he has problems of his own, and soon Stella finds herself back in the rut of misery and self-loathing that began with the child abuse hinted at in the film's flashbacks.
The director, Coky Giedroyc, has a steady control of her cast, and the three central performances are impeccably detailed. The film's flaws are in Al Kennedy's patchwork screenplay, which throws together superfluous fantasy sequences and gritty realism without regard for coherence. There is no sense of character or focus in the conception of Stella, either - it is left to the vibrant Macdonald to convey the life pulsing inside this armour-plated survivor.
But the picture has its compulsive moments, notably the taut exchanges between Bolam and Macdonald, and one scene highlighting a novel if unhygienic use for a Fisherman's Friend.
Do try and catch the new American drama The Delta on its two-week run at London's ICA. This subtle picture is sensitive in its depiction of race and class divides, focusing on Lincoln (Shayne Gray), a middle-class bisexual boy torn between the security of his girlfriend and the kick he gets from cruising the streets and bars of Memphis. At a late-night cinema he runs into the effusive Vietnamese immigrant Minh (Thang Chan), who charms the pants off him - literally. The pair take an impromptu midnight excursion on the Mississippi, which provides a refreshing escape but only complicates the choice that Lincoln will have to make come daybreak. The film has a generosity toward its characters that recalls the early films of Pasolini and Fassbinder, but its real magic is in the way it continually veers off the beaten track.
Traveller is a meandering, low-key drama whose release just happens to coincide with the appearance of new films starring its lead actors. Bill Paxton (Titanic) plays a con artist who takes young Mark Wahlberg (Boogie Nights) under his wing in the Irish-American travellers' community which is his home. Their escapades have an annoying good-ole-boy flavour; one episode is accompanied by manic banjos on the soundtrack, which momentarily make you fear the arrival of Jim Nabors. Some of the scams have the seductive flavour of those in David Mamet's House Of Games - though Mamet would never have had his characters use the proceeds from their most dangerous con-trick to fund a cute young girl's ear operation.
- More about:
- Actors And Actresses
- Cinema
- Hunting
- Theatre


text:
Logan Botanic Garden weather map
- Recent locations
Your chosen location:
City of London
An error has occurred.
Weather type
Forecast summary
Regional forecast for Dumfries, Galloway, Lothian & Borders
A bright day with a few afternoon showers.
This Evening and Tonight:
Mainly dry with bright then clear spells. Becoming cloudier over western Borders later with a few showers. Strong westerly winds, these easing a little overnight in west. Minimum Temperature 9 °C.
It will be a bright day with sunny spells and a few showers mainly in the afternoon over high ground. Fresh westerly winds easing through the afternoon. Maximum Temperature 17 °C.
Outlook for Monday to Wednesday:
Increasingly cloudy with some light rain on Monday evening. Cloudy and wet on Tuesday with fresh winds. Becoming gradually drier and brighter on Wednesday.
Updated at: 1537 on Sat 24 Jun 2017
UK forecast for the next 5 days
Rather cloudy in the south, windy in the north.
Central and southern areas will be rather cloudy but still with some warmer, brighter spells. Some light rain or drizzle is possible, mainly over western hills. Windy in the north with some blustery showers, local gales in the far north.
Strong to gale force winds in the far north. Outbreaks of rain in the northwest. Mainly fine and dry elsewhere, but further rain or drizzle possible in the southwest later.
Winds easing across all parts. Sunny spells and scattered showers in the north. Cloudier in the south with patchy rain or drizzle at first in the west, turning drier later.
Outlook for Monday to Wednesday:
Unsettled and rather cloudy, with some brighter spells. Locally heavy rain at times, especially in central and northern parts. Some thundery showers possible in the southeast, where warm at times.
Updated at: 0401 on Sat 24 Jun 2017
Outlook for the UK over the next 6-30 days
UK Outlook for Thursday 29 Jun 2017 to Saturday 8 Jul 2017:
Changeable weather is likely to continue with cloud and rain affecting most parts on Thursday, though it will be fairly warm in the north and east. Some drier and brighter periods are likely on Friday, probably in the south and west. The rest of this period will remain unsettled with showers or longer spells of rain. The showers could be heavy and thundery at times, interspersed with brief drier and brighter spells, most likely in the south and east. It will often be windy, especially in the north and west where there will be a risk of local gales at times. Temperatures are expected to drop to near normal or rather cool, especially compared to recently, although it may be warmer at times in the southeast.
Updated at: 1401 on Sat 24 Jun 2017
UK Outlook for Sunday 9 Jul 2017 to Sunday 23 Jul 2017:
The changeable weather is likely to continue in the north at first, bringing further showers or longer spells of rain with only brief bright or sunny spells in between. However, drier and warmer spells are likely to become more prevalent in the south and these may spread further north as we head into the second half of the month. These will bring more in the way of sunshine and higher temperatures, and there could be some very warm spells. However, an increase in temperatures would pose the threat of some thundery showers.
Updated at: 1402 on Sat 24 Jun 2017
Location Details
Logan Botanic Garden
Location: 54.7354, -4.9573
Altitude: 52.0 m above mean sea level


text:
Idea for a really useful thread but I need help
View Single Post
View Public Profile
Send a private message to Firefox7275
Find More Posts by Firefox7275
Join Date: Mar 2011
Posts: 3,750
Saturday, May 18, 2013 at 01:38PM
IMO there are way too many haircare products on the market to get meaningful results from a poll with numerous answers. Products are partly popular based on which country they are available in.
Reading the NC reviews (noting how many have been posted) gives you some idea of how many people are using each product. There are 7800 products in the database!
Product Search Results
2a-2c, medium texture, porous/ colour treated. Three years CG. Past bra strap length heading for waist.
CO-wash: Inecto coconut/ Elvive Volume Collagen
Treatments: Komaza Care Matani, coconut/ sweet almond/ fractionated coconut oils, Hairveda Sitrinillah
Leave in: Fructis Sleek & Shine (old), Gliss Ultimate Volume, various Elvive
Styler: Umberto Giannini jelly, Au Naturale styling gelee
Flour sack towel, pixie diffuse or air dry.
Experimenting with: benign neglect


text:
From the Department of Pulmonary Diseases and Critical Care Medicine (Dr Donohue), The University of North Carolina at Chapel Hill, Chapel Hill, NC; the Section of Pulmonary, Critical Care, and Sleep Medicine (Dr Hanania), Baylor College of Medicine, Houston, TX; the Division of Pulmonary, Critical Care, and Sleep Medicine (Dr Make), National Jewish Health, University of Colorado Denver School of Medicine, Denver, CO; the Department of Pulmonary, Critical Care, Allergy, and Immunologic Medicine (Dr Miles), Wake Forest School of Medicine, Winston-Salem, NC; the Department of Medicine (Dr Mahler), Geisel School of Medicine at Dartmouth, Hanover, NH; the Research & Development Division (Ms Curry, Mr Tosiello, and Dr Wheeler), Sunovion Pharmaceuticals Inc, Marlborough, MA; and the Department of Medicine/Division of Pulmonary and Critical Care Medicine (Dr Tashkin), David Geffen School of Medicine at UCLA, Los Angeles, CA.
CORRESPONDENCE TO: James F. Donohue, MD, FCCP, Department of Pulmonary Diseases and Critical Care Medicine, The University of North Carolina at Chapel Hill, CB# 7020, 130 Mason Farm Rd, Chapel Hill, NC 27599; e-mail: firstname.lastname@example.com
Portions of the data were presented in abstract form at the American Thoracic Society Annual Meeting, May 17-22, 2013, Philadelphia, PA (Donohue JF, Hanania NA, Make B, Curry L. Am J Respir Crit Care Med. 2013;187:A39978; Hanania NA, Donohue JF, Make B. Am J Respir Crit Care Med. 2013;187:A40227; and Make B, Hanania NA, Donohue JF. Am J Respir Crit Care Med. 2013;187:A40252) and at CHEST 2013, October 26-31, 2013, Chicago, IL (Donohue JF, Hanania NA, Make B. Chest. 2013;144[4_MeetingAbstracts]:714A and Hanania NA, Donohue JF, Make B. Chest. 2013;144[4_MeetingAbstracts]:735A).
FUNDING/SUPPORT: Research funding and financial support for medical editorial assistance was provided by Sunovion Pharmaceuticals Inc.
This is an open access article distributed under the terms of the Creative Commons Attribution-Noncommercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted use, distribution, and reproduction to noncommercial entities, provided the original work is properly cited. Information for reuse by commercial entities is available online.
Arformoterol tartrate (arformoterol, 15 μg bid) is a nebulized long-acting β2-agonist approved for maintenance treatment of COPD.
This was a multicenter, double-blind, randomized, placebo-controlled study. Patients (aged ≥ 40 years with baseline FEV1 ≤ 65% predicted, FEV1 > 0.50 L, FEV1/FVC ≤ 70%, and ≥ 15 pack-year smoking history) received arformoterol (n = 420) or placebo (n = 421) for 1 year. The primary assessment was time from randomization to respiratory death or first COPD exacerbation-related hospitalization.
Among 841 patients randomized, 103 had ≥ 1 primary event (9.5% vs 15.0%, for arformoterol vs placebo, respectively). Patients who discontinued treatment for any reason (39.3% vs 49.9%, for arformoterol vs placebo, respectively) were followed for up to 1 year postrandomization to assess for primary events. Fewer patients receiving arformoterol than placebo experienced COPD exacerbation-related hospitalizations (9.0% vs 14.3%, respectively). Twelve patients (2.9%) receiving arformoterol and 10 patients (2.4%) receiving placebo died during the study. Risk for first respiratory serious adverse event was 50% lower with arformoterol than placebo (P = .003). Numerically more patients on arformoterol (13; 3.1%) than placebo (10; 2.4%) experienced cardiac serious adverse events; however, time-to-first cardiac serious adverse event was not significantly different. Improvements in trough FEV1 and FVC were greater with arformoterol (least-squares mean change from baseline vs placebo: 0.051 L, P = .030 and 0.075 L, P = .018, respectively). Significant improvements in quality of life (overall St. George's Hospital Respiratory Questionnaire and Clinical COPD Questionnaire) were observed with arformoterol vs placebo (P < .05).
Arformoterol demonstrated an approximately 40% lower risk of respiratory death or COPD exacerbation-related hospitalization over 1 year vs placebo. Arformoterol was well-tolerated and improved lung function vs placebo.
ClinicalTrials.gov; No.: NCT00909779; URL: www.clinicaltrials.gov
COPD is a common, preventable lung disease with treatable symptoms.1 Airflow limitation is generally progressive and is partially reversible in most patients.2,3 Chronic airway and lung inflammation contributes to progressive loss of lung function in affected individuals. Worldwide, COPD exacerbations and comorbidities are a major cause of morbidity and mortality, and are associated with a high economic and social burden.1,4,5
Inadequate diagnosis and treatment of COPD are common,6,7 and may contribute to increased dyspnea, frequent exacerbations, deterioration of lung and physical function, and reduced quality of life (QoL).1,8 Major goals of COPD treatment include reducing symptoms, improving QoL, limiting exacerbations, and slowing loss of lung function.1 Depending on disease severity, patients typically experience one to three exacerbations yearly9; however, exacerbation prevalence may be substantially higher.10,11 Mortality (all-cause, lower respiratory, and cardiac) is higher among patients hospitalized for exacerbations.12 Comorbidities associated with worse prognosis and lower QoL include cardiovascular disease, osteoporosis, anxiety/depression, lung cancer, infections, metabolic syndrome, and diabetes.1
Long-acting bronchodilators may reverse airway hyperreactivity and bronchospasm in patients with asthma or COPD. Among bronchodilators, long-acting β-agonists (LABAs) have been associated with increased risk for exacerbation or death in patients with asthma13‐15 but not in patients with COPD,16,17 nor has LABA use been associated with undue risk of adverse events (AEs) in COPD. A review of 20 studies (N > 8,700) reported a low incidence of AEs and no association between LABA use and death, increased exacerbations, or COPD-related AEs.16 A history of cardiovascular disease is common in patients with COPD18; however, studies indicate comparable or somewhat lower rates of AEs, including cardiac AEs, with LABAs compared with placebo.19‐21 One exception is the potential for cardiac arrhythmias in elderly patients with cardiovascular disease.22 The US Food and Drug Administration has asked manufacturers of LABAs indicated for COPD to evaluate risks in this patient population. This trial was conducted as a postapproval commitment to further evaluate the safety of arformoterol, especially the risk of life-threatening respiratory events, such as COPD exacerbations and respiratory death, over 1 year in patients with moderate to severe COPD. Arformoterol tartrate (arformoterol) is a selective LABA administered via nebulization that is approved in the United States for maintenance treatment of bronchoconstriction in patients with COPD.23 These findings may provide clinicians with additional assurance of arformoterol safety and efficacy in patients with moderate to severe COPD.
Patients were ≥ 40 years of age with COPD, a ≥15-pack-year smoking history, and baseline Modified Medical Research Council (MMRC) Dyspnea Scale Score ≥ 2. Prebronchodilator FEV1 of ≤ 65% of predicted, FEV1 > 0.50 L, and FEV1/FVC ratio of ≤ 70% were also required. Patients were excluded for history of asthma (unless limited to childhood), life-threatening/unstable respiratory status including respiratory infection ≤ 30 days before screening, change in COPD medications ≤ 2 weeks before screening, or signs of infection ≤ 72 h before screening. An independent data and safety monitoring board monitored the study on an ongoing basis. The study was conducted in accordance with the Declaration of Helsinki and good clinical practice guidelines. Central/local institutional review boards approved the protocol, and written informed consent was obtained from all patients. Additional information on the study and patients is available in e-Appendix 1.
This was a multicenter, double-blind, randomized, placebo-controlled, parallel-group, outpatient study conducted at 71 clinical sites in the United States. Patients with moderate to severe COPD were randomized 1:1 to arformoterol or placebo (citrate-buffered saline), each administered bid via nebulization (Fig 1). Participation consisted of six visits over about 1 year (Fig 2). All patients were to be followed for 1 year postrandomization. Maintenance COPD medications other than LABAs were continued throughout the study and patients were permitted rescue albuterol (Ventolin HFA) and supplemental ipratropium use ≥ 6 h before visits. Disallowed medications and withholding periods for other long-acting bronchodilators (including tiotropium) are reported in e-Table 1.
The primary end point of this event-driven study was time from randomization to respiratory death or first COPD exacerbation-related hospitalization. Respiratory deaths were recorded when respiratory status was the primary or contributing cause of death determined by the principal investigator/medical monitor. Secondary end points included protocol-defined COPD exacerbations, mortality, AEs, and serious AEs (SAEs). Cardiac deaths were attributed similarly to respiratory deaths. Efficacy assessments included change from baseline in spirometry and QoL measures (permission was obtained for use of the St. George's Respiratory Questionnaire [SGRQ]). Patients who discontinued study treatment were followed by phone for primary events for 1 year postrandomization (e-Appendix 1).
The statistical design was based on demonstrating noninferiority, defined as a ≤ 40% higher risk (hazard ratio [HR] 1.4) of a primary event with arformoterol vs placebo. The study was powered under a one-sided alternative hypothesis, in which arformoterol was superior to placebo (HR ≤ 0.80). The HR (90% CI) for the primary assessment was estimated using a Cox proportional hazards regression model, with treatment group, baseline smoking status, sex, age, BMI, and baseline FEV1 as covariates. Other assessments are summarized descriptively (e-Appendix 1).
Patient demographics and baseline characteristics, including smoking status, MMRC dyspnea status, frequency of exacerbations, comorbid conditions, and types and frequency of medications used were evenly balanced between treatment groups (Table 1).
All patients randomized received at least one dose of study medication and comprised the ITT population. ACE = angiotensin-converting enzyme; ARF15BID = arformoterol tartrate 15 μg bid; GERD = gastroesophageal reflux disease; HMG COA = hydroxymethyl glutaryl coenzyme A; ITT = intent to treat; MMRC = Modified Medical Research Council; T2DM = type 2 diabetes mellitus.
No. = 418.
No. = 839.
Scores on the MMRC Dyspnea Questionnaire ranged from 0 to 4, with a score of 4 indicating that a patient was too breathless to leave the house or became breathless when dressing or undressing. The highest numbered question to which the patient answered "Yes" was the Dyspnea Scale Score. No patients had MMRC scores of 0 or 1; therefore, these values are omitted.
No. = 420.
No. = 840.
No patients reported smoking more than four packs/d.
Data on selective β2 adrenoreceptor agonist use represent patient concomitant medications at baseline and before visit 2, when minimum washout periods and exclusion for study duration began.
Overall, 45% of patients discontinued early from arformoterol (39.3%) or placebo (49.9%) treatment (Fig 1). Among those who discontinued, the majority discontinued arformoterol (51.5%) or placebo (60%) during the first 3 months of treatment. Most discontinuations (19.0% and 27.6%, respectively) were based on patient decision (individual reasons not reported). Discontinuations because of an AE were reported by 13.1% and 12.6% of patients, respectively. The most frequently reported AE resulting in discontinuation was COPD exacerbation in 4.5% and 6.4%, respectively.
Primary events were reported in 40 patients (9.5%) and 63 patients (15.0%) receiving arformoterol or placebo, respectively; most experienced a single event (Fig 3, Table 2). Time to respiratory death or first COPD exacerbation-related hospitalization was 171.7 days and 155 days, respectively, for patients having a primary event. Respiratory death was reported for five patients (1.2%) and eight patients (1.9%), respectively, and COPD exacerbation-related hospitalizations were reported for 38 patients (9.0%) and 60 patients (14.3%), respectively. Of note, patients experiencing COPD exacerbation-related hospitalizations could remain on study.
RCI = repeated CI. See Table 1 legend for expansion of other abbreviations.
Respiratory deaths were defined as having a probable cause related to respiratory pathophysiology.
A COPD exacerbation-related hospitalization was defined as hospitalization (any inpatient admission or ED visit lasting > 24 h, including hospice) in which the reason for admission was COPD exacerbation or in which a COPD exacerbation preceded, or occurred concomitantly with, the onset of the event for which the patient was hospitalized.
Estimated from a Cox proportional hazards model with treatment group, baseline smoking status, sex, age, BMI, and baseline FEV1 as covariates.
RCI was adjusted for planned interim analysis.
The point estimate for the primary event indicated an approximately 40% reduction in risk with arformoterol vs placebo (HR, 0.606; 90% repeated CI [RCI], 0.425, 0.864) (Fig 4, Table 2). Sensitivity analyses were conducted to assess the effect of events recorded during the follow-up period after early treatment termination. Results were consistent for all sensitivity analyses (e-Appendix 1, Fig 4).
Protocol-defined COPD exacerbations (ie, increased COPD symptoms that necessitated any change in baseline medication) were reported by 122 patients (29%) receiving arformoterol and 132 patients (31.4%) receiving placebo. Approximately 17% of patients in each group reported one event; 6.9% and 8.1% of patients, respectively, reported two events; and 5.2% and 6.2%, respectively, reported at least three events. Risks for first protocol-defined COPD exacerbation (HR, 0.801; P = .078) and recurrent protocol-defined COPD exacerbation (HR, 0.768; P = .043) were lower with arformoterol than placebo.
Patients receiving arformoterol or placebo had a similar incidence of AEs (72.9% vs 68.2%, respectively). The most frequently reported AE was an exacerbation or worsening of COPD (not protocol-defined), which was less commonly reported with arformoterol than placebo (23.3% vs 28.0% patients, respectively). The only nonrespiratory AEs occurring in ≥ 5% of patients were headache, nausea, and urinary tract infection (Table 3). Additional information on treatment-related AEs is available in e-Appendix 1.
AEs were defined as events with onset date occurring on or after the date of first dose of double-blind study medication. AE = adverse event. See Table 1 legend for expansion of other abbreviations.
The verbatim terms of COPD exacerbation, acute COPD, exacerbation of severe COPD, COPD exacerbation with hospitalization, worsening of COPD, and end-stage COPD were coded to COPD.
Twelve patients (2.9%) receiving arformoterol and 10 patients (2.4%) receiving placebo died postrandomization. In the arformoterol group, two deaths were attributed to dual SAEs (cardiorespiratory arrest and squamous cell carcinoma in one patient; pneumonia and respiratory arrest in one patient). Additionally, two deaths were attributed to myocardial infarction and one each to COPD, cardiorespiratory arrest, respiratory failure, coronary artery disease, squamous cell carcinoma, brain neoplasia, head injury, and sepsis. Seven patients receiving placebo died of COPD, and one each from pneumonia, congestive heart failure, and lung cancer.
Eighty-six patients (20.5%) and 95 patients (22.6%) receiving arformoterol or placebo, respectively, experienced SAEs (Table 4). The most frequently reported SAE was COPD exacerbation in 8.3% and 13.1% of patients, respectively. SAEs reported in ≥ 2% of patients receiving arformoterol and patients receiving placebo, respectively, included respiratory, thoracic, and mediastinal disorders (8.3% vs 14.7%), infections and infestations (5.2% vs 6.4%), cardiac disorders (3.1% vs 2.4%), and GI disorders (2.1% vs 2.4%).
SAEs were defined as events with onset date occurring on or after the date of first dose of double-blind study medication. Reports of SAEs were collected from the time of informed consent to 30 d after last scheduled dose. For patients who discontinued treatment before completing the study, primary events and other fatal events were collected up to 1 y after randomization. SAE = serious adverse event. See Table 1 legend for expansion of other abbreviations.
Time-to-event analyses (defined as the time from randomization until the first event onset date) were conducted for first SAE, respiratory SAE, cardiac SAE, and AE resulting in discontinuation of study treatment. Risk for a first respiratory SAE was about 50% lower with arformoterol than placebo (HR, 0.508; P = .003). Time-to-first SAE and time-to-first AE resulting in discontinuation were numerically longer, whereas time-to-first cardiac SAE was numerically shorter with arformoterol than placebo. No statistically significant treatment differences were observed (e-Appendix 1, Table 5).
See Table 1, 3, and 4 legends for expansion of abbreviations.
Twenty patients (14 placebo and six arformoterol) experienced a first SAE after treatment discontinuation +30 d (while still being monitored) and were censored in the time-to-first SAE analysis; therefore, n = 81 and n = 80 patients in the placebo and arformoterol arms, respectively.
Hazard ratio, 95% CI for the hazard ratio, and Wald test P value were from a Cox proportional hazards regression model for time-to-first event with treatment group, baseline smoking status, sex, age, and baseline FEV1 values as covariates.
Results of clinical assessments, including laboratory findings, vital signs, and ECG results are described in e-Appendix 1.
Arformoterol demonstrated greater improvements from baseline in lung function at 1 year vs placebo (Table 6). Arformoterol significantly improved trough FEV1 from baseline (least-squares mean [LSM] difference vs placebo: 0.051 L; P = .030). Similarly, arformoterol significantly improved % predicted FEV1 from baseline (LSM difference, 1.448; P = .039) and trough FVC from baseline (LSM difference, 0.075 L; P = .018), whereas change in trough inspiratory capacity (IC) from baseline was not significantly greater with arformoterol (LSM difference, 0.045 L; P = .125). Absolute mean values for change in FEV1 were comparable to LSM values reported herein. See e-Appendix 1 and e-Table 2 for QoL assessments and rescue medication use.
IC = inspiratory capacity; LSM = least squares mean. See Table 1 legend for expansion of other abbreviations.
n = 420 at baseline and overall.
Overall treatment effect from the repeated measures linear model for change from baseline with covariates for treatment, baseline smoking status, baseline IC, baseline IC-by-visit interaction, visit, and the treatment-by-visit interaction. P values were unadjusted for multiplicity.
n = 416 at baseline and overall.
The primary objective of this phase 4 trial (ie, postapproval commitment) in patients with COPD was to determine whether long-term use of arformoterol was associated with fatal and life-threatening respiratory events, which had been observed in studies of LABA-containing products in patients with asthma.14,15,24 In this study, arformoterol demonstrated an approximately 40% lower risk of respiratory death or COPD exacerbation-related hospitalization over 1 year vs placebo, suggesting that, in this study population, no such association was detected. Patients receiving arformoterol experienced fewer protocol-defined COPD exacerbations, fewer respiratory SAEs, and a significantly lower risk (about 50%; P = .003) of a first respiratory SAE vs placebo. Cardiac SAEs were numerically higher with arformoterol than placebo (HR, 1.059; P = .905). Arformoterol significantly improved QoL measures (SGRQ total score, Symptoms and Impacts individual scores, and Clinical COPD Questionnaire [CCQ] score) (e-Fig 1) from baseline vs placebo. Improvements in lung function (ie, mean placebo-adjusted increase in trough FEV1 of 51 mL) were consistent with those observed with other approved bronchodilators in a population with mostly severe airflow limitation who were receiving substantial background therapy.25 Findings were consistent with previous studies demonstrating that arformoterol is an effective and tolerable COPD maintenance therapy, and no safety signal suggestive of drug-related, life-threatening respiratory or cardiac events was evident.4,26‐28
The safety and efficacy of LABAs and long-acting muscarinic antagonists in COPD have been demonstrated in several trials. The first two trials were long-term "mega trials"—Understanding Potential Long-term Impacts on Function with Tiotropium (UPLIFT) (tiotropium) and Towards a Revolution in COPD Health (TORCH) (salmeterol/fluticasone propionate combination).29,30 Although neither long-term trial achieved significant primary outcomes (reduction in lung function decline over 4 years in UPLIFT or reduction in all-cause mortality after 3 years in TORCH), they demonstrated that long-acting bronchodilators reduce exacerbation rates and improve health status and QoL with no increased mortality risk or an excess of cardiac SAEs. An additional trial of note assessed the effect of triple therapy (budesonide/formoterol plus tiotropium) over 12 weeks.31 Although this trial supports the administration of long-acting bronchodilators in combination with inhaled corticosteroids (about 57% of current-study patients), its short duration does not permit definitive conclusions regarding long-term efficacy and safety. The current 1-year study demonstrates the safety and efficacy of arformoterol and provides reassurance that LABAs do not increase the risk of exacerbations or respiratory death in patients with COPD.
Study strengths include a large patient cohort with long-term treatment data. Importantly, 1-year efficacy data for pulmonary function measures provide additional information on the effects of nebulized bronchodilator treatment against a background of naturally declining lung function. A noninferiority statistical design was used; however, arformoterol was superior to placebo based on an upper bound of the HR (90% RCI) point estimate of 0.606 (0.425, 0.864) being < 1.0 (null value of no treatment difference). Sensitivity analyses assessing the impact of treatment follow-up, important protocol deviations, and baseline covariates support the primary analysis that arformoterol did not increase the risk of respiratory death or COPD exacerbation-related hospitalizations vs placebo during 1 year of treatment.
There were several study limitations. There was a low baseline exacerbation rate of about one COPD exacerbation in the prior year (low-moderate risk). It is unclear what effect a lower baseline exacerbation rate would have on study outcomes. However, because sample size was driven by the number of primary events observed, the likely impact was only on the number of patients needed for enrollment. Other baseline characteristics (including percent-predicted FEV1 of about 40%) indicate a population with fairly severe disease (based on GOLD [Global Initiative for Chronic Obstructive Lung Disease] guidelines in effect at study initiation). If patients in the current study were reassessed using the current GOLD evaluation criteria (eg, symptoms, exacerbation history, and exacerbation rates at baseline), one would expect a more complete picture of exacerbation risk, but not necessarily of mortality risk. There were also a high number of patient withdrawals from treatment (but not withdrawals from study). Forty-five percent of patients discontinued arformoterol (39.3%) and placebo (49.9%) during the study; however, among 841 randomized patients, only 89 (10.6%; 42 arformoterol, 47 placebo) were not followed for 1 year. The discontinuation rate is comparable to, albeit at the higher end of, the range observed in other long-term COPD studies (27%-44%).28‐30 Patient-initiated discontinuation was more common with placebo than arformoterol (a finding that may be related to lack of efficacy, as has been discussed previously32), although this was not assessed as an independent reason for withdrawal. Discontinuations occurred primarily during the first 3 months of treatment.
The effect of discontinuations on incidence of primary events was assessed in a sensitivity analysis (e-Table 3). Specifically, how many events would need to occur in patients who discontinued vs patients who completed the trial to overturn the findings for superiority and noninferiority of arformoterol? The incidence of the primary end point would have to be fivefold higher (about 50% vs about 10%) in arformoterol dropouts than in completers to overturn the superiority finding, and > 20-fold higher to overturn the noninferiority finding. We believe that this analysis provides reassurance that the number of discontinuations postrandomization in this study would not affect our conclusions.
In conclusion, this long-term safety study demonstrates that arformoterol did not increase the risk of respiratory death or COPD exacerbation-related hospitalizations vs placebo during 1 year of treatment. These results are consistent with findings in the 3-year TORCH study that demonstrated the long-term safety of LABAs in patients with COPD.29 In addition, patients receiving arformoterol experienced improvements in lung function and QoL measures vs patients receiving placebo.
Author contributions: J. F. D. takes final responsibility for the content of this manuscript, including the data and analysis. J. F. D., N. A. H., B. M., M. C. M., D. A. M., L. C., R. T., A. W., D. P. T. contributed to data analysis and interpretation, writing, critical review and revision, and final approval of the published version; N. A. H., B. M., and L. C. contributed to study conduct; L. C. and R. T. contributed to study design; and R. T. contributed to the plan on statistical analysis.
Financial/nonfinancial disclosures: The authors have reported to CHEST the following conflicts of interest: Dr Donohue is a consultant to and serves on the advisory committee for Sunovion Pharmaceuticals Inc. Dr Hanania is a consultant to Boehringer Ingelheim GmbH, GlaxoSmithKline plc, Mylan Inc, Novartis AG, Pearl Therapeutics, Inc, Pfizer Inc, and Sunovion Pharmaceuticals Inc, and provides institutional support for conduct of study to Sunovion Pharmaceuticals Inc. Dr Make is a consultant to and serves on the advisory committee for Sunovion Pharmaceuticals Inc; is a speaker/advisor for AstraZeneca, Boehringer Ingelheim GmbH, GlaxoSmithKline, Forest Laboratories Inc, Pfizer Inc, Respironics, Merck & Co Inc, Coviden, Aerocrine, and Theravance; and has received grants from AstraZeneca, Forest Laboratories Inc, Sunovion Pharmaceuticals Inc, GlaxoSmithKline, Boehringer Ingelheim GmbH, Pfizer Inc, and NABI. Dr Miles is a consultant to Sunovion Pharmaceuticals Inc. Dr Mahler is a consultant to, and provides institutional support for conduct of study to, Boehringer Ingelheim GmbH; is a consultant to and serves on the advisory committee for Forest Laboratories, Inc; is a consultant to, serves on the advisory committee for, and provides institutional support for conduct of study to GlaxoSmithKline plc; serves on the advisory committee for Merck & Co, Inc; is a consultant to, serves on the advisory committee for, and provides institutional support for conduct of study to Novartis AG; serves on the advisory committee for Pearl Therapeutics, Inc; and is a consultant to, serves on the advisory committee for, and provides institutional support for conduct of study to Sunovion Pharmaceuticals Inc. Ms Curry, Mr Tosiello, and Dr Wheeler are employees of Sunovion Pharmaceuticals Inc. Dr Tashkin serves on the advisory committee and is a speaker for AstraZeneca; received a research grant from and is a speaker for Boehringer Ingelheim GmbH; is a speaker for Forest Laboratories, Inc; received a research grant from GlaxoSmithKline plc; serves on the advisory committee for, received a research grant from, and is a speaker for Novartis AG; received a research grant from Pearl Therapeutics, Inc; received a research grant from and is a speaker for Pfizer Inc; and serves on the advisory committee for and received a research grant from Sunovion Pharmaceuticals Inc.
Role of sponsors: The sponsor had no role in the design of the study, the collection and analysis of the data, or the preparation of the manuscript.
Other contributions: We thank John O'Flaherty, PhD, of ProEd Communications Inc, a Healthcare Consultancy Group Company, for his medical editorial assistance with this manuscript.
Additional information: The e-Appendix, e-Figure, and e-Tables can be found in the Supplemental Materials section of the online article.
adverse event
hazard ratio
inspiratory capacity
long-acting β-agonist
least-squares mean
Modified Medical Research Council
quality of life
repeated CI
serious adverse event
Towards a Revolution in COPD Health
Online Supplement
Become a CHEST member and receive a FREE subscription as a benefit of membership.
Individuals can purchase this article on ScienceDirect.
Individuals can purchase a subscription to the journal.
Individuals can purchase a subscription to the journal or buy individual articles.
Learn more about membership or Purchase a Full Subscription.
Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 3
Customize your page view by dragging & repositioning the boxes below.
Enter your username and email address. We'll send you a reminder to the email address on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.


text:
EUR/USD Continues Decreasing as Greek Worries Persist
EUR/USD Open 1.4171 High 1.4307 Low 1.4101 Close 1.4182
On Friday the Euro/Dollar continued weakening as Greek worries persist, decreasing with 165 pips. The European currency depreciated from 1.4307 to 1.4140 on Friday, matching the negative Interbank sentiment projection at bellow -1%, closing the week at 1.4182. This morning the European currency descended even further, dropping down to 1.4101. On the 1 hour chart the downward channel is making renewal attempts, while on the 3 hour chart trading remains within wide range. Break above the nearest resistance and Friday's top at 1.4307 may trigger further strengthening of the Euro. Going bellow today's bottom and first support at 1.4101, however, would confirm continuation of the bearish trend, towards next important objective downwards 1.3988. There are no major economic events for EU today. Quotes are moving bellow 20 and 50 EMA on the 1 hour chart, indicating bearish pressure. The value of the RSI indicator is negative and declining, MACD is negative and quiet, while CCI has crossed down the 100 line on the 1 hour chart, giving overall short signals.
Technical resistance levels: 1.4307 1.4420 1.4536
Technical support levels: 1.4101 1.3988 1.3870
Trading range: 1.4140 - 1.4065
Trend: Downward
Sell at 1.4127 SL 1.4157 TP 1.4077
On Friday we made +50 pips profit on EUR/USD from the following signal:
5:29 GMT+1 Sell EUR/USD at 1.4264 SL 1.4290 TP 1.4214, TP reached at 8:23 GMT+1.
Total on Friday +130, as shown in details here.


text:
With 1.7 million freelancers, we'll match you with the perfect talent.
I am an experienced .Net solution provider from India with a strong experience of more than 8 years and good communication skills. I have proven experience in design, development, deployment, analysis of complex software products for web as well as desktop application.
I have worked with renowned companies from India for long time on varied projects in different domains with utmost efficiency, hence quality and timely delivery will never be a concern. I have also worked with client from the US, UK, Germany, Australia etc on projects in...


text:
9 months ago
Web Marketing Tips For Getting Results Now
If your business is important to you, then Affiliate marketing should also be important. Do not expect people to find your site if you do not promote it. Internet promotion may be all that stands between a stagnant business and a flourishing one. The following tips will show you hot to be successful at Internet promotion.
Put a link to your website in every signature area you can. If you post in a forum, you can usually link to your site right in your signature, which will make it appear with every post you make. It should appear at the bottom of your emails as well. This ensures that your website address is out in public areas for all to see. You never know who may stumble across it,


text:
We are happy about your use of this app. The protection of your data is an important matter to us and we want you to feel safe when using our app.
In the following we will explain which data you can record and how this information is used.
Via our app you can record favourites (telephone, mail, SMS and WhatsApp) that get triggered fast via the widget. For entering data, we need access to the address book. If you select a contact,
the iOS standard dialogues (SMS-dialogue, mail-dialogue, telephone-dialogue, …) get activated. For that reason, you don´t have to enter personal data (like email account).
All entered data lies in a protected area of the device and cannot be read by lawful means.
We neither have access to this data, nor are any hidden messages being sent to us.
A backup of data takes place either locally in an accessible section of the device or in the Cloud of the company Apple, provided that this function is activated in the operating system iOS of the respective device.
All data can be deleted entirely and at any time from within the app.
We assure you that we do not have any access to your data and that we do not log any information outside of the app.
Christian Drapatz
Kämpenstrasse 42
45147 Essen (Germany)
+49 (0)171 7849462 (No Support)
ios (at) onetwoapps.com
Christian Drapatz
Kämpenstrasse 42
45147 Essen (Germany)
Mobil: +49 (0)171 7849462
(No Support)
E-Mail: support(at)onetwoapps.com
E-Mail: support(at)onetwoapps.de


text:
Techs use an eco-friendly solution that kills mosquitos and prevents them from breading so you can enjoy your yard bite-free
1 - 37 of 74 results
Discover new restaurants, spas, things to do & more great deals added daily!
You can change your email preferences at any time
By clicking Continue, I agree to the Terms of Service and Privacy Statement
No Thanks
*Valid on 1 unit per transaction; max 1 Local deal per customer. Max discount $25. New customers only. Exclusive and non-transferable. Ends 6/30/17. Full details: gr.pn/promofaq


text:
Ukraine International Airlines flight PS776 schedule
Flight departure days
Flight schedule & details, June 26
1. Flight PS776: Tel Aviv - Kiev, TLV - KBP, 3h 25m
International flight PS776 by Ukraine International Airlines serves route from Israel to Ukraine (TLV to KBP). The flight departs Tel Aviv, Ben Gurion terminal «3» on June 26 14:15 (2:15 pm) and arrives Kiev, Boryspil on June 26 17:40 (5:40 pm). Flight duration is 3h 25m.
Ukraine International Airlines
14:15 / 2:15 pm
17:40 / 5:40 pm
June 26, Monday
June 26, Monday
Terminal 3
Ben Gurion (TLV)
Boryspil (KBP)
Tel Aviv, Israel
Kiev, Ukraine
Flight duration: 3h 25m
Boeing 737-800
Alternative and return flights
See also
Check flight ticket price and book the flight Tel Aviv - Kiev
New search by flight number
Flight number
Search alternative directions
Origin airport
Destination airport


text: Select an international website Zoover.at Zoover.be Zoover.ch Zoover.co.uk Zoover.com.br Zoover.com.tr Zoover.com.ua Zoover.cz Zoover.de Zoover.dk Zoover.es Zoover.fi Zoover.fr Zoover.gr Zoover.hu Zoover.it Zoover.lt Zoover.nl Zoover.no Zoover.pl Zoover.pt Zoover.ro Zoover.ru Zoover.se Home Destinations Accommodations Awards Add review Add review Add photos Add videos Add new accommodation Add attraction Home Add review Germany Rhineland-Palatinate Schuld Accommodations Schuld Reviews (0) Photos & videos (26) Accommodations (2) Attractions (7) Weather forecast Map Tips (0) More Question and Answer (0) Appreciation 8.0 Nightlife 7.0 Culture 5.0 Surroundings 9.0 Atmosphere 7.0 Weather 15° / 24° 26 Jun 2017 Weather forecast and climate... 8 1 Review Are you looking for a well-reviewed accommodation for your holiday in Schuld? Below you are able to find all accommodations in Schuld. Sort by Zoover recommends Rating Reviews Distance from center 2 Accommodations Germany, Rhineland-Palatinate, Schuld Location Radius: Select 2 km 10 km 20 km 50 km Country Germany Region Rhineland-Palatinate Destination Schuld User Rating Number of reviews 1 5 Review 8.5-10 Very good1 7-8.4 Good1 Contributions 1 Search within results: 8.6 click Add review Hotel: Zur Linde Schuld, 0 km from center Germany Rhineland-Palatinate Schuld 8 click Add review Hotel: Schäfer Schuld Germany Rhineland-Palatinate Schuld Hotels Hotels in Trier Hotels in Cochem Hotels in Koblenz Hotels in Bernkastel-Kues (Moezel) Hotels in Andernach Hotels in Traben-Trarbach (Moezel) Hotels in Boppard Information about Schuld Weather Schuld Map Schuld Photos Schuld Videos Schuld Question and Answer Schuld Nearby destinations Adenau (Eifel) Wershoven Insul Kottenborn Kirchsahr Rodder Fuchshofen Are you looking for a well-reviewed accommodation for your holiday in Schuld? Below you are able to find all accommodations in Schuld. Schuld scores a 8.0 out of 10, based on 1 reviews read more Are you looking for a well reviewed accommodation for your holiday in Schuld? Below you are able to find all accommodations in Schuld. You are able to find reviews about 2 Hotels in Schuld. To find your perfect accommodation, please use the filters on the left side. On top of that you will find 26 vacation photos of Schuld on Zoover. - - - Less text


text:
President Ronald Reagan once said:
"Freedom is never more than one generation away from extinction. We didn't pass it to our children in the bloodstream. It must be fought for, protected, and handed on for them to do the same, or one day we will spend our sunset years telling our children and our children's children what it was once like in the United States where men were free."
The following are symptoms of the NWO "National Mind Control"
- Illusion of Invulnerability: Members ignore obvious danger, take extreme risk, and are overly optimistic.
- Collective Rationalization: Members discredit and explain away warning contrary to group thinking.
- Illusion of Morality: Members believe their decisions are morally correct, ignoring the ethical consequences of their decisions.
- Excessive Stereotyping: The group constructs negative stereotypes of rivals outside the group.
- Pressure for Conformity: Members pressure any in the group who express arguments against the group's stereotypes, illusions, or commitments, viewing such opposition as disloyalty.
- Self-Censorship: Members withhold their dissenting views and counter-arguments.
- Illusion of Unanimity: Members perceive falsely that everyone agrees with the group's decision; silence is seen as consent.
- Mind guards: Some members appoint themselves to the role of protecting the group from adverse information that might threaten group complacency.
It will soon be a crime to think against the NWO. So, while we still have time let us join one another in working, speaking, writing, thinking, about what future we desire to live in. Let us come together and build that which is still possible before the NWO has it's own version of the 'night of long knives.'


text:
|Message view
|« Date » · « Thread »
|« Date » · « Thread »
|"Steven J. Owens" <puffm...@darksleep.com>
|Re: What is the best book about Servlets/Jsp?
|Thu, 20 Feb 2003 18:50:19 GMT
On Thu, Feb 20, 2003 at 01:41:43PM -0500, Erik Price wrote: > Mike Jackson wrote: > >However I'll agree, I don't look at the books often, usually by this > >point I go to the java docs. > > I'll second this, the javadocs are much quicker than going to a book now > that I know where to look for stuff. The book was just a great way to > get the basics down. And for clarification on some things I peruse the > spec, though I haven't had time to actually read it straight through. The javadocs are indispensable and what I use the majority of the time, for reference. Reading the specs can be really useful, particularly the servlet spec (read the servlet spec *before* you read the JSP spec), but if you're new to this stuff, you may want to get a more gentle introduction. For further, detailed recommendations from me and some other folks see the end of: http://darksleep.com/puff/writings/j2eeoverview.html You may also find the rest of the article useful, as it's a quick and dirty overview of JSPs, servlets and EJBs. It might give you enough of the "lay of the land" to figure out where to start. Steven J. Owens email@example.com "I'm going to make broad, sweeping generalizations and strong, declarative statements, because otherwise I'll be here all night and this document will be four times longer and much less fun to read. Take it all with a grain of salt." - Me at http://darksleep.com --------------------------------------------------------------------- To unsubscribe, e-mail: email@example.com For additional commands, e-mail: firstname.lastname@example.com
|View raw message


text:
Posted by Steve
It may have come later than expected, but we finally have a trade to analyze. The Brewers dealt Jim Edmonds to the Reds for outfielder Chris Dickerson.
Edmonds was the most likely player to be traded out of any Brewer this season. He was on a one-year deal and performed well in a platoon role. At 40 years old, it makes sense to send him to a contender rather than have him (possibly) finish up his career on a bad team. Plus, the Brewers are thankfully committing to playing Lorenzo Cain in center for the rest of the season. There was no reason for them to play Edmonds over Cain at this point.
As far as the trade itself, I'm very pleased with the return. I don't see how anyone couldn't be impressed by it, actually. They turned a non-roster Spring Training invite into a Major League outfielder with four remaining years of team control. I'm very surprised the Reds gave up a major-league ready player; I assumed the Brewers would have to take a flyer on some low-level prospect. Dickerson is a talented outfielder who plays all three outfield positions well. He's a defensive upgrade to Ryan Braun and Corey Hart, and he's an offensive upgrade to Carlos Gomez. He doesn't have a ton of pop in his bat, but in parts of three seasons, Dickerson has a .367 on-base percentage. His ability to get on base could allow the Brewers to move Rickie Weeks down in the lineup to a run-producing spot after Prince Fielder is dealt this off-season.
A few random thoughts on this deal: It's interesting to note that the Brewers seem to have gotten a better return for a 40-year old Jim Edmonds than they did for J.J. Hardy last year. I also chuckle at the thought of Dusty Baker considering Dickerson expendable because he doesn't value walks. Finally, this trade reminds me very much of the one for Jody Gerut last season. Gerut could have been described in the same way as Dickerson: an outfielder with on-base skills but not much power who can play all three outfield positions. Gerut, to my surprise, has not worked out–I'm guessing his time in Milwaukee has run out. I expect Dickerson to have more success.
This gives the Brewers plenty of options for next season. I'd like to see Lorenzo Cain given every opportunity to be the full time center fielder. Unlike Alcides Escobar or Carlos Gomez, Cain has actually earned that opportunity by hitting in the minors. Gomez has a minor league option left; he should be sent to AAA to play full time. Maybe he'll actually hit. If not, let him go or just settle on him as a fifth outfielder. An outfield of Braun, Hart, Cain, Dickerson, and Gomez sounds good to me. Dickerson can spell any of the three starters against tough righties. He would also be a good candidate for a semi-regular platoon outfielder should the Brewers choose to move Hart or even Braun to first base.
As far as remaining waiver deals, I would not be surprised to see Craig Counsell traded soon. Like Edmonds, at his advanced age, Counsell has no purpose on a team that's going nowhere. He has value to a contending team as a utility infielder, and the Brewers should get whatever they can for him.


text:
European shares inch up early; Infineon dips after results
* FTSEurofirst 300 up 0.2 pct, DAX up 0.4 pct
* DAX gains ground for 11th straight session
* Energy shares under pressure ahead of OPEC meeting
By Blaise Robinson
PARIS, Nov 27 (Reuters) - European shares inched up in early trade on Thursday, adding to their recent sharp rally that has been fuelled by expectations of further stimulus measures from the European Central Bank.
Infineon dropped 1.9 percent after the German auto and industrial chipmaker posted results that slightly missed analyst forecast.
Remy Cointreau surged 6 percent after the French spirits group - whose cognac sales have been hurt by a Chinese government crackdown on ostentatious spending - reported a smaller-than-expected drop in profit.
"The results are better-than-expected, thanks to sales from its liquor and spirits division, as well as better cost control," a Paris-based trader said.
At 0900 GMT, the FTSEurofirst 300 index of top European shares was up 0.2 percent at 1,391.69 points. Continuación...


text:
Your browser does not support iframes.
TELL CITY – Mr. and Mrs. Joe Scarboro of Tell City celebrated their 45th wedding anniversary with family and friends Saturday, June 10, at the Tell City Moose Lodge.
Mr. Scarboro and the former Marlene Sutcliffe were married June 10, 1972, at Lilly Dale Church of Christ.
They have two children, John Scarboro of Tell City and Cathy (Matt) Board of Leopold.
They have six grandchildren, Katelin, Kaylee and Ashley Scarboro, Tyler and Dylan Watson and Myles Board.
TIPSAW – The 15th annual Adventures with Nature field day will be held at Tipsaw Lake, on Saturday, June 24. Activities will get underway at 9 a.m. CST and will conclude approximately 1 p.m. This event is made possible by the collaborative efforts of Perry & Spencer County Soil and Water Conservation Districts, Purdue Extension Perry County and the USDA Forest Service.
TELL CITY – Golden Living Center Lincoln Hills will hold a cocktails and paint party Monday, July 24, at the Tell City Moose Lodge at 5:30 to 8:30 pm.
All proceeds will go toward the Walk to End Alzheimer's Team. The annual Walk will be in Jasper on Sept. 30. There are 12 paint pieces to choose from and the fee ranges from $30-40 depending on choice.
By JAKE BETHEL
Feature Writer
TELL CITY – Perry County native Carly Jarboe has developed an original style of painting, inspired by her family.
Jarboe attends Indiana University Southeast in New Albany. She has been accepted into the bachelor of fine arts program, in which she will major in painting and minor in ceramics. She was awarded the Martha Stem Fine Arts Scholarship, worth $3,000, after only one year at the school.
TELL CITY – Local cancer survivors and their caregivers will take the celebratory first lap at the annual American Cancer Society Relay For Life of Perry County event on Saturday, June 17, at City Hall Park in Tell City.
The presses at Abbey Press in St. Meinrad are silent now. The stitchers, trimmers and binders, noisy for decades, are idle and the offices and cubicles of the sprawling sandstone building fronting Indiana 545 are empty. So are the warehouses half a mile down the highway.
Abbey Press has all but closed and an online auction will offer much of the equipment later this month.
State Rep. Lloyd Arnold
District 74
Indiana's unemployment rate is continuing to fall each month. In general, economists agree that a rate below 5 percent indicates a strong economy. Currently, our statewide unemployment rate is at 3.6 percent. This is lower than the national average of 4.4 percent, and it is lower than all four of our bordering states.
U.S. Rep. Larry Bucshon
Guest Columnist
The opioid abuse epidemic has taken a heartbreaking toll here in Indiana and across the country.
While we still have much work to do, over the past couple of years we've made significant progress to bring hope to our communities and expand access to treatment for those who need it.
Vince Luecke
editor@perry countynews.com
I seldom dream.
I should say I seldom remember dreams. Everyone dreams often, sleep researchers say. But a dream Wednesday night has to go into the Top 5 ranking of my most vivid dreams. Perhaps because it woke me up and I stewed about its contents most of the morning.
Copyright © 2017
The Perry County News is your source for local news, sports, events, and information in Perry County, Indiana, and the surrounding area.


text:
How to Grab Maharaja Whiteline CLEO JX-115 Juicer Mixer Grinder
- Visit here for offer page
- Add to cart
- Login or register
- No coupon Req.
- Pay the amount..
Features of Maharaja Whiteline CLEO JX-115 Juicer Mixer Grinder:
- Juicer Mixer Grinder
- 450 W Heavy Duty Motor
- Stainless Steel
- Juicer Mesh
- Non Slip Foot
- Pulp Container
Note: Make cart value above 500 to avoid shipping Rs. 40 or subscribe for Flipkart First membership at Rs. 500 for 1 year to get free shipping.
Additional Tips for Save More on Flipkart while Shopping
- Visit here For – Today Best Offers of Flipkart
- Flipkart App Download Flipkart Mobile App


text:
If you thought they were done, you thought wrong!
The Marshall Tucker Band is going on the road again, and could be visiting a city near you. The Southern rock/country band made their iconic entrance into the music scene during the 1970's, but their tremendous success has carried their career to 2016.
The band announced that they won't be "riding off into the sunset" just yet on their website. The year of 2016 is scheduled full of concert dates for the group, so if you're a fan, get ready!
The Marshall Tucker Band hasn't released new music since 2013, but timeless classics like "Can't You See", "Heard It in a Love Song", "Take the Highway", and many more are sure to make an appearance on the set list.
See if they will be visiting a city near you by checking the calendar on their website. Click here for details or check the list we have below.
2/20 Stadium Theatre - Woonsocket, RI
2/21 Infinity Music Hall & Bistro - Hartford, CT
2/27 Carl Perkins Civic Center - Jackson, TN
3/4, 3/5 Orleans Hotel & Casino - Las Vegas, NV
3/10 Key West Theater - Key West, FL
3/11 Pompano Beach Amphitheater - Pompano Beach, FL
3/12 Jesters Live @ Destination Daytona - Ormond Beach, FL
3/17 Stanley Center for the Arts - Utica, NY
3/18 Magic City Music Hall - Binghampton, NY
3/19 The Paramount - Huntington, NY
3/25 Hollywood Casino - Toledo, OH
4/2 Rhythm n' Ribs Festival - St. Augustine, FL
4/4 Neel Performing Arts Center - Bradenton, FL
4/16, 4/17 Southern Ground Music & Food Festival - Charleston, SC
4/21 Dosey Doe - The Woodlands, TX
Watch Marshall Tucker Band's live 1977 performance of "Can't You See" below.
Interested in becoming a partner?
Contact us for more info.


text:
St. John's (Antigua), Jan 12: West Indies on Sunday (January 11) announced their 15-man squad for the ICC World Cup to be held in Australia and New Zealand in February and March. The side will be captained by Jason Holder, who was the captain for the ODI series against South Africa, while Marlon Samuels has been appointed Holder's deputy.( See full itinerary of WC 2015)
Former captain Dwayne Bravo and Kieron Pollard were left out from the squad while off-spinner Sunil Narine, who was reported twice for suspect bowling action during the Champions League T20 (CLT20) in India last year, was included.
West Indies will play their opening World Cup match on February 16 against Ireland before going on to face Pool B rivals, defending champions India, South Africa, Pakistan, Zimbabwe and the United Arab Emirates.
The West Indies team will also play two warm-up games against England and Scotland on February 9 and 12 respectively.
West Indies Squad for WC 2015
Jason Holder (captain), Marlon Samuels (vice-captain), Sulieman Benn, Darren Bravo, Jonathan Carter, Sheldon Cottrell, Chris Gayle, Sunil Narine, Denesh Ramdin, Kemar Roach, Andre Russell, Darren Sammy, Lendl Simmons, Dwayne Smith, Jerome Taylor.
West Indies Itinerary at WC 2015
Vs Ireland (Feb 16), vs Pakistan (Feb 21), vs Zimbabwe (Feb 24), vs South Africa (Feb 27), vs India (Mar 6), vs U.A.E. (Mar 15)
Oneindia News


text:
New finds to brighten up your living space.
Your coupon will be applied to the highest regular-price, eligible item in your cart.
Offer good for one item at regular price only. Limit one coupon per customer per day. Must present coupon at time of purchase. Offer is not valid with any other coupon, discount or previous purchase. One cut or one bolt of fabric or trim "by the yard" equals one item. Online fabric & trim discount is limited to 10 yards, single cut. Excludes Heidi Swapp™ Minc.™ Foil Applicator, CRICUT® products, Gemini Machine™ Crafters Companion, Silhouette CAMEO® Machine, candy & snack products, gum & mints, helium tanks, gift cards, custom orders, special orders, labor, rentals or class fees. Cash Value 1/10¢.
New finds to brighten up your living space.
Discover what DIY dreams are made of.
Stitch the days away with next-level fabrics.
Paper projects worth whipping up? Yes, please.
Celebrate summer with refreshing florals.
Ring in patio season with funky party supplies.
Supplies to cheer on your inner artist.
This way to the freshest needle-art supplies.
Look here for summery goodies galore.
Make statement jewelry your new thing.
Wear what you love. Love what you wear.
Harness the building blocks of your imagination with Creative Bric Tek Pack! With an assortment of blocks, doors, and figures, this kit will have you on your way to creating expertly crafted block structures. Create, build, and play!
Box contains 440 pieces.
Note: Number of pieces may vary.
I love it! Add to wish list


text:
Detached house in Kassandra, Halkidiki has 80 m² floor area. There is a living room with a fireplace, kitchen, two bathrooms and two bedrooms. It has fitted kitchen and closets and has an outdoors storage room and 400 m² garden.
Villa – Kassandreia, Administration of Macedonia and Thrace, Greece
200,000 €
Land area: 80 m²
- Built in 1962
- 1-floor building
- Total rooms: 2
- Garden


text:
|Next book >>
Napoleon Must Die(1993)
(The first book in the Victoire Vernet series)
A novel by Quinn Fawcett
When her husband is unjustly accused of theft and murder in Napoleonic France, Mme. Victoire Vernet sets out to clear his name and finds herself in the middle of a plot to assassinate Napoleon.
Used availability for Quinn Fawcett's Napoleon Must Die
See all available used copies of this book at Abebooks UK or Abebooks US
Paperback Editions
August 1993 : USA Paperback
|Title: Napoleon Must Die: A Mme. Vernet Investigation
Author(s): Quinn Fawcett
ISBN: 0-380-76541-1 / 978-0-380-76541-6 (USA edition)
Publisher: Avon Books (Mm)
Availability: Amazon Amazon UK Amazon CA
Kindle Editions
April 2013 : USA, Canada, UK Kindle edition
|Title: Napoleon Must Die (Mme Vernet Book 2)
Author(s): Chelsea Quinn Yarbro, Bill Fawcett
Publisher: Event Horizon EBooks/Britton Knowles Publishing Group
Availability: Amazon Amazon UK Amazon CA
Genre Pages


text:
Our vision is to guide and prepare all students to make academic and behavioral decisions that will define their options in high school and beyond.
Our mission is to achieve excellence through our daily habits and high expectations.
AP Mr. Randall, AP Ms. Taliaferro, Principal Mrs. Whiteman, AP Mr. Jones